Our findings are consistent with the idea that SHP2 inhibitors alter the neurofibroma microenvironment via direct effects on tumor cells and through direct effects on immune cells in the bone marrow and in circulation before they are recruited into tumors. The gene discussed is PTPN11; the disease is neurofibroma.